Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Biosimilar Regulation Headaches From Morocco To Pakistan

Executive Summary

Delegates at the recent pre-ICDRA conference heard about the issues dogging the regulation of biosimilar medicines in the Eastern Mediterranean Region, including unfamiliarity with the comparability exercise and a lack of expertise and resources in this area. The question of a "global comparator product" was also raised.

You may also be interested in...

Biosimilar Sponsors Say Pharmacokinetic Bridging Studies Should Be The Exception, Not The Norm

US FDA guidance runs risk of creating de facto requirement for bridging studies when a biosimilar applicant seeks to use comparative data involving a foreign reference product, Novartis says; IGBA, AAM urge agency adopt a ‘global comparator’ approach that would eliminate the need for clinical bridging studies between US and foreign reference biologics.

WHO Kick-Starts Pilot For Prequalification Of Biologics/Biosimilars

Manufacturers are being invited to submit expressions of interest in relation to two anticancer monoclonal antibodies on the WHO's essential list of medicines.

WHO To Review Impact Of Mechanism For Tackling Substandard & Falsified Drugs

Recent incidents of illness and death caused by contaminated cough syrups show that there is a need to review the “member state mechanism” that is intended to coordinate efforts to tackle poor quality medical products, the World Health Organization says.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts